WFH/X
Jul 29, 2025, 13:12
AAV Gene Therapies for Hemophilia A and B: Current Perspectives
The World Federation of Haemophilia (WFH) shared a proud post on X:
“Gene Therapy is transforming Hemophilia care. A new review highlights how AAV-based treatments for hemophilia A and B are delivering long-term results—some lasting years with just one dose. Challenges remain, but the future is promising.
Read more.”
Title: Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Authors: Roland W. Herzog, Radoslaw Kaczmarek, Katherine A. High
Stay informed with Hemostasis Today.
-
May 28, 2026, 13:42Claudio Laudani: Balancing Ischemic and Bleeding Risk in AF with Coronary Disease
-
May 28, 2026, 13:30When it Comes to Stroke Care, Quality Matters – Duke Health
-
May 28, 2026, 13:29Natalie Johnson: Transforming PE Care Through Endovascular Innovation
-
May 28, 2026, 13:16Francisco Chacón-Lozsán: Anticoagulation Strategies for Complex ICU Patients
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia
-
May 28, 2026, 12:36Kabilan K L: Key Nursing Considerations for Abciximab Therapy
-
May 28, 2026, 12:17Astha Thakkar: Practical Approaches to Platelet Thresholds in ITP
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early